NIV NAVA in pediatric acute respiratory failure.

How can it help to improve patient’s outcome?

Watch our webinar featuring Prof. Daniele De Luca now! During this 60 minute event, Prof. De Luca discussed the results of a controlled before-after quality improvement study, published in 2021 in the “Anesthesia, Analgesia and Critical Care” journal. 
 
This study shows that NIV-NAVA, delivered as first-line noninvasive respiratory support (NRS) in pediatric moderate AHRF of infectious origin, is associated with a lower intubation rate, shorter PICU and hospital length of stay, as well as early improvement of physiological parameters compared to NIV-PS traditional treatment including endotracheal intubation and mechanical ventilation.